Valneva SE (VALN) Free Cash Flow (2021 - 2026)
Valneva SE (VALN) posted Free Cash Flow of -$76098.5 for Q1 2026, up 99.81% sequentially from -$40.0 million in Q4 2025, and up 98.86% YoY from -$38267.8 in Q1 2025.
Valneva SE (VALN) Free Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE has reported Free Cash Flow for 6 years, with the latest figure at -$76098.5 in Q1 2026.
- Quarterly Free Cash Flow rose 98.86% year-over-year to -$76098.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.5 million (up 12.96% YoY) and the FY2025 annual result came in at -$66.7 million, up 23.98% from the prior year.
- Free Cash Flow climbed to -$76098.5 in Q1 2026 per VALN's latest filing, from -$40.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $62.6 billion in Q3 2023 and troughed at -$62.7 billion in Q2 2023.
- A 5-year average of -$40.7 million and a median of -$21.5 million in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 75346.38% in 2023, down 88979.7% in 2023.
- Over 5 years, Free Cash Flow stood at -$110.8 million in 2022, then gained by 13.2% to -$96.2 million in 2023, then soared by 82.33% to -$17.0 million in 2024, then plunged by 135.17% to -$40.0 million in 2025, then surged by 99.81% to -$76098.5 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$76098.5, -$40.0 million, and -$17.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -16.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.58 Mn |
| Jun 30, 2026 | -16.58 Mn |
| Mar 31, 2026 | -76,098.47 |
| Mar 31, 2026 | -76,098.47 |
| Dec 31, 2025 | -39.96 Mn |
| Dec 31, 2025 | -39.96 Mn |
| Sep 30, 2025 | -17.86 Mn |
| Sep 30, 2025 | -17.86 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | -6.66 Mn |
| Mar 31, 2025 | -6.66 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | -40.11 Mn |
| Jun 30, 2024 | -40.11 Mn |
| Mar 31, 2024 | -25.86 Mn |
| Mar 31, 2024 | -25.86 Mn |